- In February 2024, Riverain Technologies, a U.S.-based leader in AI imaging diagnostics, expanded the deployment of its ClearRead CT software across multiple hospital networks in North America. This advanced computer-aided detection tool enhances lung nodule visibility in low-dose CT scans, enabling earlier and more accurate diagnosis of lung cancer. The expansion marks a significant step in the use of AI for radiology and highlights Riverain's commitment to empowering clinicians with innovative diagnostic technologies to improve patient outcomes
- In January 2024, the American College of Radiology (ACR) launched an updated version of its Lung Cancer Screening Registry (LCSR), which includes enhanced software features for data tracking, analytics, and reporting. The update is designed to support healthcare providers in complying with CMS reporting requirements and to facilitate more comprehensive lung cancer screening program management. This move reflects the growing emphasis on evidence-based screening supported by integrated software tools across U.S. hospitals and imaging centers
- In December 2023, Aidoc, an AI health tech company headquartered in the U.S., announced a partnership with several large U.S. health systems to deploy its AI-based triage and workflow optimization software for lung cancer screening. The partnership aims to improve case prioritization and reduce turnaround times in radiology departments. This development underscores the increasing demand for intelligent, interoperable solutions to handle growing volumes of CT screenings efficiently
- In October 2023, the Canadian Partnership Against Cancer (CPAC) rolled out a national lung cancer screening framework that incorporates AI-driven software platforms to improve early detection. As part of the initiative, select provinces have begun integrating digital tools to manage patient enrollment, track screening outcomes, and standardize workflows. This development highlights Canada's push to scale lung cancer screening programs through digital health innovation and federal support
- In August 2023, Volpara Health, a medical software company with operations across North America, introduced a lung cancer screening module as part of its broader cancer risk assessment suite. The software is designed to help clinicians identify high-risk patients using demographic, behavioral, and genetic data. This integration offers a more personalized approach to lung cancer screening, reflecting a regional shift toward precision medicine and proactive population health management
